Embolic Protection

Cath Lab Digest contains unique articles and information on the topic of embolic protection. Feel free to browse through our articles below.

Distal Embolic Protection: A routine part of interventional procedures in the near future Cath Lab Digest talks with Donald S. Baim, MD Distal Embolic Protection: A routine part of interventional procedures in the near future Cath Lab Digest talks with Donald S. Baim, MD Feature: Distal Embolic Protection: A routine part of interventional procedures in the near future Cath Lab Digest talks with Donald S. Baim, MD - Professor of Medicine, Harvard Medical School, Director, Center for Integration of Medicine and Innovative Technology, Brigham and Women's Hospital, Boston, Massachusetts Why do you think that distal embolic ...

News from the Transcatheter Cardiovascular Therapeutics Meeting (TCT) Held in Washington, D.C., October 16-21, 2005

Embolic Protection ? Its Role in Carotid, Coronary and Renal Intervention Abstract. The end-organ consequences of arteriosclerosis, namely heart attack, stroke and renal failure, are the leading cause of mortality and morbidity in the western world. Advances in percutaneous interventional techniques have meant that a fair proportion of this disease burden can be dealt with by percutaneous and nonsurgical options. Coronary angioplasty is an established way of dealing with simple and increasingly complex coronary disease. Carotid and renal stenting are also gaining favor as the preferred treatment options, compared to either medical therapy or surgical treatment. Overall, the endovascular approach to treating increasingly complex arterial atherosclerosis is increasing. As the use of stenting increases, so the drive to reduce potential complications and improve success rates intensifies. Although embolization from local atheroma has long been recognized as a potential complication in vascular surgery, direct evidence of this phenomenon was also observed during saphenous vein graft angioplasty. There is also evidence that similar embolization also occurs during carotid and renal stenting, and in certain native coronary lesions with a high thrombus burden. This review examines the rationale for the use of embolic protection systems during endovascular intervention and the clinical evidence base for their use. We also describe the different types of embolic protection systems currently available, their relative merits and outline recommendations for the current use of these devices. This article is reprinted with permission from Vascular Disease Management 2007;4(2):49?58.

Invasive Cardiology News II The Zipper technology: ? ? Patient relations dilemmas ?

Carotid Artery Stenting: Case Selection, Training Requirements and Recommendations for a Successful Procedure On March 17, 2005, the Centers for Medicare and Medicaid Services (CMS) issued a decision memorandum supporting the use of carotid artery stenting (CAS) with embolic protection as a reasonable and necessary treatment for symptomatic patients having a carotid artery stenosis ≥ 70%, and symptomatic or asymptomatic patients enrolled in a clinical trial or a post market surveillance study who have a 50?70% stenosis or ≥ 80% stenosis, respectively. Patients within each of the three categories must be considered at high risk of complications from carotid endarterectomy (CEA). The CMS decision was based on supportive safety and efficacy data of a randomized clinical trial that compared CEA to CAS (SAPPHIRE by Cordis Corporation) and a CAS registry (ARCHeR by Guidant Corporation) that compared results to historical controls. Several low-risk CAS clinical trials or registries are in progress; the objective of these being a comparison of major adverse cardiac and cerebrovascular events (MACCE) and longer term efficacy following CAS or CEA in conjunction with optimal medical management.

Clinical and Industry News for August 2006 Results of Hospital Performance Measures Do Not Always Reflect Patient Outcomes Hospital quality measures do not fully account for the variation in hospital death rates for heart attack patients, according to a study in a recent issue of the Journal of the American Medical Association. a follow-up study of breast cancer, including evaluating potential genetic influences on breast cancer risk; and ? In 1983, the University of Minnesota, National Cancer Institute, and American Registry of ...

Clinical and Industry News System U.S. Study to Start by the end of November Kensey Nash Corporation has commenced a trial of the new version of the TriActiv® Embolic Protection System for carotid stenting procedures in a European Pilot study. System, the second generation of the TriActiv System, is commercialized in Europe and has been studied in the 100-patient ASPIRE Study registry to support clearance in the U.S. Evalve Announces Intiation of Trial of Percutaneous Alternative to Open-Heart Mitral Valve Surgery ...

Clinical and Industry News for April 2007 The minimally invasive placement of the device will allow the transformation of the treatment of chronic heart failure patients from the acute decompensated hospitalized patient to the chronic, ambulatory heart failure patient. Mobile Aspects can be found on the web at www.mobileaspects.com. Boston Scientific Announces Program to Improve Anti-Platelet Compliance for DES Patients Boston Scientific Corporation announced a program designed to improve patient compliance with physician-prescribed...

Research Update 462) Chronic Total Occlusions A New Percutaneous Porcine Coronary Model of Chronic Total Occlusion Authors: Woohyuk Song, Jaeung Lee, Hyunjoong Kim, Jinho Shin, Dongjoo Oh, Fermin Tio, S. Chiu Wong, Mun K. Hong Objective: Chronic total occlusion (CTO) of coronary arteries represents a challenge for percutaneous treatment. Embolic Protection Device Performance Evaluation in the Carotid Artery During Percutaneous Transluminal Angioplasty and/or Stenting Author: Alberto Cremonesi Recently ...

Clinical and Industry News Cont. - Abbott Announces New Trial in Stroke Prevention: ACT I ACT I will study the potential benefits of minimally invasive carotid stenting in patients who normally would have surgery Abbott will begin enrolling patients during the first quarter of 2005 in its asymptomatic carotid trial, ACT I. This multi-center, randomized trial will compare carotid artery stenting to carotid artery surgery in asymptomatic patients who normally would be referred for surgery. Carotid Angioplasty and Stenting vs...